This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caragine, T. A. Articles by Tomlinson, S. Search for Related Content PubMed PubMed Citation Articles by Caragine, T. A. Articles by Tomlinson, S.

A Tumor-expressed Inhibitor of the Early but not Late Complement Lytic Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer¹

Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina 29425 [T. A. C., S. T.]; Department of Molecular Biology, Nagoya City University, School of Medicine, Nagoya, 4678601 Japan [N. O.]; and Department of Cell Biology and Kaplan Cancer Center, New York University School of Medicine, New York, New York 10016 [A. B. F.]

Membrane-bound complement inhibitors protect host cells from inadvertent complement attack, and complement inhibitors are often up-regulated on tumors, possibly representing a selective adaptation by tumors to escape elimination by a host antitumor immune response. Relevant in vivo studies using rodent models of human cancer have been hampered by the fact that human complement inhibitors are not effective against rodent complement. Using nude rats and MCF7 cells expressing different rat complement inhibitors, a model of human breast cancer was established to investigate the role of complement and complement inhibitors in tumor progression. Expression of rat CD59, an inhibitor of the terminal cytolytic membrane attack complex of complement, had no effect on the incidence or growth rate of MCF7 tumors. In contrast, expression of rat Crry, an inhibitor of complement activation, dramatically enhanced the tumorigenicity of MCF7 cells. The expression of rat Crry on MCF7 inhibited the in vivo deposition of complement C3 fragments that serve as opsonins for receptors on phagocytes and natural killer cells. These data provide direct in vivo evidence that an inhibitor of complement activation can facilitate tumor growth by modulating C3 deposition. These data indicate an important role for complement opsonization in promoting cell-mediated antitumor immune function, a conclusion further supported by the demonstration that expression of rat Crry, but not rat CD59, on MCF7 cells inhibits rat cell-mediated cytotoxicity in vitro. Rat complement activation on MCF7 tumors was mediated by tumor-reactive antibodies present in the serum of naïve nude rats, but there was also an IgM response to MCF7 tumors, a situation with similarities to some human cancers. These data support a hypothesis that blocking complement inhibitor function on tumor cells will not only enhance monoclonal antibody-mediated immunotherapy but may also be effective at enhancing a normally ineffective humoral immune response in the absence of administered antitumor antibody.

This article has been cited by other articles:

				S. M. Mangsbo, J. Sanchez, K. Anger, J. D. Lambris, K. N. Ekdahl, A. S. Loskog, B. Nilsson, and T. H. Totterman Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects J. Immunol., November 15, 2009; 183(10): 6724 - 6732. [Abstract] [Full Text] [PDF]

				E. Racila, B. K. Link, W.-K. Weng, T. E. Witzig, S. Ansell, M. J. Maurer, J. Huang, C. Dahle, A. Halwani, R. Levy, et al. A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma Clin. Cancer Res., October 15, 2008; 14(20): 6697 - 6703. [Abstract] [Full Text] [PDF]

				M. Imai, R. Ohta, J. C. Varela, H. Song, and S. Tomlinson Enhancement of Antibody-Dependent Mechanisms of Tumor Cell Lysis by a Targeted Activator of Complement Cancer Res., October 1, 2007; 67(19): 9535 - 9541. [Abstract] [Full Text] [PDF]

				D. V. Rozanov, A. Y. Savinov, V. S. Golubkov, S. Tomlinson, and A. Y. Strongin Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res., June 15, 2006; 66(12): 6258 - 6263. [Abstract] [Full Text] [PDF]

				D. V. Rozanov, A. Y. Savinov, V. S. Golubkov, T. I. Postnova, A. Remacle, S. Tomlinson, and A. Y. Strongin Cellular Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Cleaves C3b, an Essential Component of the Complement System J. Biol. Chem., November 5, 2004; 279(45): 46551 - 46557. [Abstract] [Full Text] [PDF]

				R. Ohta, N. Kondor, N. Dohi, S. Tomlinson, M. Imai, V. M. Holers, H. Okada, and N. Okada Mouse Complement Receptor-Related Gene y/p65-Neutralized Tumor Vaccine Induces Antitumor Activity In Vivo J. Immunol., July 1, 2004; 173(1): 205 - 213. [Abstract] [Full Text] [PDF]

				K. A. Gelderman, P. J. K. Kuppen, N. Okada, G. J. Fleuren, and A. Gorter Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases Model Cancer Res., June 15, 2004; 64(12): 4366 - 4372. [Abstract] [Full Text] [PDF]

				T. A. Caragine, M. Imai, A. B. Frey, and S. Tomlinson Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity Blood, October 16, 2002; 100(9): 3304 - 3310. [Abstract] [Full Text] [PDF]